Low-dose versus standard-dose bacille Calmette–Guérin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Se Young | - |
dc.contributor.author | Ha, Moon Soo | - |
dc.contributor.author | Kim, Jung Hoon | - |
dc.contributor.author | Chi, Byung Hoon | - |
dc.contributor.author | Kim, Jin Wook | - |
dc.contributor.author | Chang, In Ho | - |
dc.contributor.author | Kim, Tae-Hyoung | - |
dc.contributor.author | Myung, Soon Chul | - |
dc.date.accessioned | 2022-04-05T07:40:07Z | - |
dc.date.available | 2022-04-05T07:40:07Z | - |
dc.date.issued | 2022-03 | - |
dc.identifier.issn | 2466-0493 | - |
dc.identifier.issn | 2466-054X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/55802 | - |
dc.description.abstract | Purpose: Intravesical BCG (bacille Calmette–Guérin) instillation in patients with non-muscle-invasive bladder cancer decreases the risk for tumor recurrence and progression. After one BCG product was discontinued, a chronic global BCG shortage occurred. We focused on identifying a reduced dose of BCG that could maintain efficacy and reduce adverse effects.Materials and Methods: We conducted a comprehensive literature search of PubMed, Embase, the Cochrane Library, CINAHL, Web of Science, and Scopus to identify randomized controlled trials through April 2021. The odds ratios (ORs) and 95% confidence intervals (CIs) for the low and standard doses in nine studies were compared. A low dose was defined as a low volume of BCG compared with the standard BCG dose (Armand Frappier, 120 mg; Connaught, 81 mg; Danish 1331, 120 mg; modified Danish 1331, 120 mg; Tokyo 172, 80 mg).Results: The low-dose group experienced aggravated recurrence (OR, 1.45; 95% CI, 1.09–1.94; p=0.01) but similar progression (OR, 1.11; 95% CI, 0.76–1.62; p=0.59), similar cancer-specific survival (OR, 1.02; 95% CI, 0.60–1.75; p=0.93), similar overall survival (OR, 1.09; 95% CI, 0.76–1.56; p=0.65), favorable adverse effects (OR, 0.41; 95% CI, 0.28–0.62; p<0.0001), and favorable withdrawal (OR, 0.42; 95% CI, 0.25–0.71; p=0.001). Conclusions: Low-dose BCG had more unfavorable outcomes than did standard-dose BCG in terms of recurrence. Tumor progression, cancer-specific survival, and overall survival were similar between the doses. Low-dose BCG improved adverse effects and withdrawal. In the setting of BCG shortage, low-dose BCG may have strong potential as an alternative. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한비뇨의학회 | - |
dc.title | Low-dose versus standard-dose bacille Calmette–Guérin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials | - |
dc.type | Article | - |
dc.identifier.doi | 10.4111/icu.20210340 | - |
dc.identifier.bibliographicCitation | Investigative and Clinical Urology, v.63, no.2, pp 140 - 150 | - |
dc.identifier.kciid | ART002818342 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000813508000003 | - |
dc.identifier.scopusid | 2-s2.0-85125883980 | - |
dc.citation.endPage | 150 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 140 | - |
dc.citation.title | Investigative and Clinical Urology | - |
dc.citation.volume | 63 | - |
dc.type.docType | Review | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Administration | - |
dc.subject.keywordAuthor | intravesical | - |
dc.subject.keywordAuthor | Adverse effects | - |
dc.subject.keywordAuthor | Recurrence | - |
dc.subject.keywordAuthor | Urinary bladder neoplasms | - |
dc.subject.keywordPlus | T1 PAPILLARY CARCINOMA | - |
dc.subject.keywordPlus | HIGH-RISK TA | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | MAINTENANCE | - |
dc.subject.keywordPlus | STRAINS | - |
dc.subject.keywordPlus | BCG | - |
dc.subject.keywordPlus | INSTILLATION | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordPlus | MG | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.